|
| 37421230 | Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways. | Genes Chromosomes Cancer | 2024 |
| 36550359 | BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. | Oncogene | 2023 |
| 37657465 | Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer. | Lancet Oncol | 2023 |
| 37993149 | Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. | BMJ Open | 2023 |
| 35410957 | Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review. | Thorax | 2023 |
| 37167572 | Family Matters: Germline Testing in Thoracic Cancers. | Am Soc Clin Oncol Educ Book | 2023 |
| 34930610 | Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. | J Thorac Oncol | 2022 |
| 35654055 | Abemaciclib for malignant pleural mesothelioma - Authors' reply. | Lancet Oncol | 2022 |
| 35706488 | Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. | EClinicalMedicine | 2022 |
| 35637530 | Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. | Genome Med | 2022 |
| 35462085 | Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. | J Thorac Oncol | 2022 |
| 35358455 | Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. | Lancet Oncol | 2022 |
| 35778611 | Immunotherapy approaches for malignant pleural mesothelioma. | Nat Rev Clin Oncol | 2022 |
| 35588752 | EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. | Lancet Oncol | 2022 |
| 36505807 | Corrigendum: <i>CDKN2A</i> determines mesothelioma cell fate to EZH2 inhibition. | Front Oncol | 2022 |
| 35999308 | Accelerating innovations in systemic therapy for pleural mesothelioma. | Nat Cancer | 2022 |
| 35990583 | Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. | EClinicalMedicine | 2022 |
| 35157829 | Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 34973224 | CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. | Lancet Oncol | 2022 |
| 33155719 | Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. | Histopathology | 2021 |
| 33795785 | Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. | Sci Rep | 2021 |
| 33741915 | Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. | Nat Commun | 2021 |
| 33515503 | Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. | Lancet Respir Med | 2021 |
| 34994590 | Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment. | JCO Precis Oncol | 2021 |
| 34588615 | Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma. | Br J Cancer | 2021 |
| 34551230 | Perspectives on the Treatment of Malignant Pleural Mesothelioma. | N Engl J Med | 2021 |
| 34518291 | Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. | J Immunother Cancer | 2021 |
| 34277422 | <i>CDKN2A</i> Determines Mesothelioma Cell Fate to EZH2 Inhibition. | Front Oncol | 2021 |
| 34099722 | Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. | Nat Commun | 2021 |
| 34067960 | Precision Therapy for Mesothelioma: Feasibility and New Opportunities. | Cancers (Basel) | 2021 |
| 33158996 | BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. | Mol Cancer Ther | 2021 |
| 31065954 | A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. | Invest New Drugs | 2020 |
| 31829907 | Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). | J Clin Oncol | 2020 |
| 32669375 | Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial. | Clin Cancer Res | 2020 |
| 32448904 | ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. | Eur J Cardiothorac Surg | 2020 |
| 32184261 | EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. | J Cell Sci | 2020 |
| 32437439 | Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature. | PLoS One | 2020 |
| 32451346 | ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. | Eur Respir J | 2020 |
| 31103412 | Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. | Lancet Respir Med | 2019 |
| 31976036 | Mesothelioma: Hippo pathway as a target, lessons from COMMAND. | Oncotarget | 2019 |
| 31329517 | Reply to K. Masuda et al. | J Clin Oncol | 2019 |
| 31470129 | Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. | J Thorac Oncol | 2019 |
| 31406306 | Cancer-cell death ironed out. | Nature | 2019 |
| 31260832 | Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. | J Thorac Oncol | 2019 |
| 31628017 | Tumour Treating Fields for mesothelioma: controversy versus opportunity. | Lancet Oncol | 2019 |
| 31367541 | A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. | Transl Lung Cancer Res | 2019 |
| 30863365 | When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All? | Front Endocrinol (Lausanne) | 2019 |
| 30785827 | Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. | J Clin Oncol | 2019 |
| 29345617 | Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. | Elife | 2018 |
| 30244849 | Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. | J Thorac Oncol | 2018 |